



## Vimovo® (naproxen/esomeprazole magnesium) – First-time generic

- On February 27, 2020, [Dr. Reddy's launched](#) an [AB-rated](#) generic version of Nuvo's [Vimovo \(naproxen/esomeprazole magnesium\)](#) delayed-release tablets.
- Vimovo is approved in adult and adolescent patients 12 years of age and older weighing at least 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk for developing naproxen-associated gastric ulcers.
- Vimovo carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.
- According to IQVIA Health, Vimovo had U.S. sales of approximately \$414 million for the twelve months ending in December 2019.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.